Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Translational Oncology Research International Genentech |
---|---|
Information provided by: | Translational Oncology Research International |
ClinicalTrials.gov Identifier: | NCT00203424 |
The purpose of this study is to evaluate the safety and effectiveness of bevacizumab plus erlotinib following radical prostatectomy.
Condition | Intervention | Phase |
---|---|---|
Prostate Cancer |
Drug: Erlotinib Drug: Bevacizumab |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Phase II Trial of Adjuvant Bevacizumab and Erlotinib in Patients at High Risk for Early Relapse Following Radical Prostatectomy for Prostate Cancer |
Estimated Enrollment: | 30 |
Study Start Date: | June 2005 |
This study explores the anti-tumor activity of adjuvant bevacizumab plus erlotinib in a select group of prostate cancer patients deemed at high risk for early relapse following radical prostatectomy.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Jim Muff | (310) 824-1934 | jm@tori.org |
Contact: Nancy Ryba, RN | (310) 794-6500 | nryba@mednet.ucla.edu |
United States, California | |
Cancer Care Associates Medical Group, Inc. | Recruiting |
Redondo Beach, California, United States, 90277 | |
Contact: Sherry Hutcherson, RN 310-750-3376 | |
Principal Investigator: David Chan, MD | |
Central Coast Medical Oncology Corporation | Recruiting |
Santa Maria, California, United States, 93454 | |
Contact: Alison Fernandez, RN 805-349-9393 | |
Principal Investigator: Robert Dichmann, MD | |
Central Hematology Oncology Medical Group, Inc. | Recruiting |
Alhambra, California, United States, 91801 | |
Contact: Helene Yang 626-588-2825 | |
Principal Investigator: Eddie H. Hu, MD | |
Comprehensive Blood and Cancer Center | Recruiting |
Bakersfield, California, United States, 93309 | |
Contact: Lori Glass 661-862-7158 | |
Principal Investigator: Ravi Patel, MD | |
Sansum Santa Barbara Medical Foundation Clinic | Recruiting |
Santa Barbara, California, United States, 93105 | |
Contact: Margot Jakab 805-569-7459 | |
Principal Investigator: Julie A. Taguchi, MD | |
Pacific Shores Medical Group | Recruiting |
Long Beach, California, United States, 90813 | |
Contact: Teresa Olea, RN 562-590-0345 | |
Principal Investigator: Andre Kiem Dian Liem, MD | |
San Diego Cancer Center | Not yet recruiting |
Vista, California, United States, 92081 | |
Contact: Christine DeFrancisco, RN 760-598-1700 | |
Principal Investigator: Mark J. Adler, MD | |
North Valley Hematology/Oncology Medical Group | Recruiting |
Northridge, California, United States, 91328 | |
Contact: Pamela Riach, RN 818-885-8500 ext 2832 | |
Principal Investigator: Sheldon J. Davidson, MD | |
Santa Barbara Hematology Oncology Medical Group, Inc. | Recruiting |
Santa Barbara, California, United States, 93105 | |
Contact: Margot Jakab 805-569-7459 | |
Principal Investigator: Frederic C. Kass, MD | |
UCLA Medical Center | Recruiting |
Los Angeles, California, United States, 90095 | |
Contact: Nathalie Chorn, RN 310-825-4493 | |
Principal Investigator: Fairooz Kabbinavar, MD | |
Ventura County Hematology-Oncology Specialists | Recruiting |
Oxnard, California, United States, 93030 | |
Contact: Pamela Riach, RN 805-485-8709 | |
Principal Investigator: Rosemary E McIntyre, MD | |
Virginia K. Crosson Cancer Center | Recruiting |
Fullerton, California, United States, 92835 | |
Contact: Gayle Madden-Mathes, RN 714-446-5804 | |
Principal Investigator: Richard E. Lloyd, MD | |
Wilshire Oncology Medical Group, Inc. | Recruiting |
Pomona, California, United States, 91767 | |
Contact: Viet Pham 909-596-5333 | |
Principal Investigator: Linda D. Bosserman, MD | |
United States, Florida | |
Cancer Institute of Florida, P.A. | Not yet recruiting |
Orlando, Florida, United States, 32804 | |
Contact: Jane Crofton, RN 407-303-2090 | |
Principal Investigator: Rebecca L. Moroose, MD | |
United States, Nevada | |
Comprehensive Cancer Centers of Nevada | Recruiting |
Las Vegas, Nevada, United States, 89109 | |
Contact: Eve Stork, RN 702-952-3400 ext 5422 | |
Contact: Donna Katz, RN 702-952-3444 ext 5525 | |
Principal Investigator: Heather J. Allen, MD | |
United States, Texas | |
South Texas Oncology and Hematology, P.A. | Recruiting |
San Antonio, Texas, United States, 78207 | |
Contact: Sandra Hendricks 210-593-2634 | |
Contact: Dolly Fischer 210-616-7978 | |
Principal Investigator: Gladys I. Rodriguez, MD |
Study Chair: | Fairooz Kabbinavar, MD | Chief Medical Officer, TORI |
Study ID Numbers: | TORI GU-01 |
Study First Received: | September 13, 2005 |
Last Updated: | March 7, 2006 |
ClinicalTrials.gov Identifier: | NCT00203424 |
Health Authority: | United States: Food and Drug Administration |
Erlotinib Prostatic Diseases Genital Neoplasms, Male Urogenital Neoplasms |
Bevacizumab Genital Diseases, Male Prostatic Neoplasms |
Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Growth Substances Physiological Effects of Drugs Enzyme Inhibitors Angiogenesis Inhibitors Protein Kinase Inhibitors |
Pharmacologic Actions Neoplasms Neoplasms by Site Therapeutic Uses Angiogenesis Modulating Agents Growth Inhibitors |